Parkinson’s disease: Transitioning from symptom control to d...
The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
Newsletters and Deep Dive digital magazine
The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.
Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.
InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition.
Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.
Rare neurology is not defined by a lack of scientific opportunity or capital.
Editor's Picks
Newsletters and Deep Dive
digital magazine